Lilly says Cialis is gaining on Viagra

Share this article:
Eli Lilly said Cialis is gaining market share from the top-selling erectile dysfunction (ED) drug, Pfizer’s Viagra. Cialis has gained more than 3% of global market share between July 2005 and July 2006, Lilly said during a presentation to analysts. Sales of Cialis continue to grow in most markets around the globe, including the US, Europe and Latin America. Cialis is on track to be the No. 1 ED drug worldwide -- excluding the US -- by next year, Lilly said. Viagra had 49.3% of the global market as of July, while Cialis had 35.5%, Lilly said. Third-place Levitra, made by GlaxoSmithKline, had about 15.3% of the market. Lilly did not make any claims for overtaking Viagra inside the US, where Viagra holds 58% of the market, compared with 25% for Cialis, Worldwide, Cialis sales are expected to top $1 billion in 2007, which would make it one of Lilly's top five drugs. Cialis is a top-selling ED drug in 17 countries, including France, where it is commonly referred to as "le weekender." Lilly will launch Cialis next year in Japan. Lilly is buying its Cialis marketing partner, Seattle-based Icos, for about $2.1 billion. Cialis' patent does not expire until 2017.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...